Quotient Limited to Participate in the Cowen 41st Annual Healthcare Conference
Quotient Limited (NASDAQ:QTNT) will present at the Cowen 41st Annual Healthcare Conference on March 1, 2021, at 1:20 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Quotient Limited (NASDAQ:QTNT) will present at the Cowen 41st Annual Healthcare Conference on March 1, 2021, at 1:20 PM ET. The presentation will be available via live webcast on the company's investor relations page, with a replay archived for 90 days. Quotient specializes in transfusion diagnostics, aiming to transform diagnostics practices through its innovative MosaiQ technology, which offers fully automated, consolidated testing. Their MosaiQ COVID-19 Antibody Microarray has earned CE marking and FDA Emergency Use Authorization.
Details
News Market Reaction – QTNT
The recorded move for QTNT in the trading session of this news was -2.37%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
JERSEY, Channel Islands, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that the Company will present at the Cowen 41st Annual Healthcare Conference on Monday, March 1, 2021 at 1:20pm ET.
A webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.quotientbd.com. A webcast replay will be archived on the website for approximately 90 days.
About Quotient Limited
Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. In response to the global effort to combat COVID-19, Quotient developed the MosaiQ COVID-19 Antibody Microarray which is CE marked and has received the U.S. FDA Emergency Use Authorization. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.
The Quotient logo, Quotient MosaiQ and MosaiQ are trademarks or registered trademarks of Quotient Limited or its subsidiaries in various jurisdictions.
Contact: Peter Buhler, Chief Financial Officer, IR@quotientbd.com; +41 22 545 52 26
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.